Skincare-Focused Innovation Labs
Niagen Bioscience has launched its Skincare Innovation Lab, introducing Niagen NanoCloud, a water-activated powder sachet containing nicotinamide riboside (Niagen) and other beneficial ingredients. This program aims to translate the science behind their Tru Niagen supplement line into visible skin benefits, focusing on improving skin texture, hydration, and radiance. The innovation highlights trends in water-activated formulations, topical NAD+ precursors, and the integration of bioscience with skincare for enhanced efficacy.
JPMorgan Chase & Co. Makes New $3.68 Million Investment in Niagen Bioscience, Inc. $NAGE
JPMorgan Chase & Co. has made a new investment of $3.68 million in Niagen Bioscience, Inc. (NASDAQ:NAGE), acquiring 394,166 shares, representing 0.49% ownership. Analyst sentiment is positive, with a "Moderate Buy" rating and an average price target of $16, significantly higher than the current share price of $4.38. Niagen Bioscience, a bioscience firm focusing on NAD+ research, has a market capitalization of $350.75 million, with institutional investors holding approximately 15.41% of its stock.
Tru Niagen gains traction with expert backing, Niagen Bioscience expands reach
Tru Niagen is gaining significant momentum in the health supplement market, supported by endorsements from prominent scientists like Stanford professor Andrew Huberman and biomedical scientist Rhonda Patrick. Niagen Bioscience, the company behind Tru Niagen, recently announced its Q4 and fiscal 2025 financial results and secured a headline sponsorship for the NAD for Health conference in Copenhagen, further solidifying its presence in the NAD+ research sector. These developments are enhancing the brand's reputation and sparking increased consumer interest in NAD+ supplementation.
Canaccord Lowers Niagen Bioscience, Inc. (NAGE) PT on Updated Forecasts Following Q4 Results
Canaccord Genuity has revised its price target for Niagen Bioscience, Inc. (NAGE) to $13 from $14, while maintaining a Buy rating, following the company's strong Q4 results and continued demand for its main product lines. Additionally, Niagen Bioscience announced an increase in its share repurchase program from $10 million to $20 million, demonstrating a commitment to returning capital to shareholders. The company, known for its Tru Niagen supplements, is also exploring growth opportunities in its injectable segment.
12 Penny Stocks with Insider Buying in 2026
This article highlights Niagen Bioscience, Inc. (NASDAQ: NAGE) as one of the top penny stocks with significant insider buying in 2026. The company recently received a "Buy" rating from Canaccord Genuity, despite a slight price target revision, and announced an expansion of its share repurchase program, signaling confidence from management and a commitment to shareholder value. Niagen Bioscience focuses on NAD⁺ research and healthy-aging solutions, known for its Tru Niagen supplements.
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
Niagen Bioscience has partnered with OneSpaWorld to offer its pharmaceutical-grade Niagen IV in over 80 Medi-Spa clinics on high-end cruise ships. This collaboration marks Niagen Bioscience's first venture into cruise ship clinics, expanding its Niagen Plus footprint and making its NAD-boosting IV available to travelers seeking wellness experiences at sea. The partnership aims to provide a premium, science-backed solution for healthy aging to a new consumer base.
Niagen Bioscience, Inc. (NASDAQ:NAGE) Short Interest Down 13.6% in March
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) short interest decreased by 13.6% in March, totaling 5,578,868 shares, which represents about 7.7% of its shares outstanding. The stock opened at $4.28, trading near its 1-year low, and analysts maintain a consensus "Moderate Buy" rating with a target price of $16.00. Several institutional investors adjusted their holdings in the company during the fourth quarter.
Niagen Bioscience (NAGE) price target decreased by 13.92% to 13.87
This article reports a significant price target decrease for Niagen Bioscience (NAGE). The target was lowered by 13.92% to 13.87. Further details regarding the reasons for this adjustment are not provided in the snippet.
Niagen Bioscience (NASDAQ:NAGE) Upgraded at Wall Street Zen
Niagen Bioscience (NASDAQ:NAGE) was upgraded from a "hold" to a "buy" rating by Wall Street Zen, contributing to a consensus "Moderate Buy" rating with a target price of $16.00. The company's stock opened at $4.20, with a market capitalization of $336.3 million, and institutional investors hold approximately 15.4% of its shares. Other analyst firms have also provided ratings, with Canaccord Genuity Group maintaining a "buy" rating but lowering its price objective to $13.00, and Weiss Ratings reaffirming a "hold" rating.
Niagen Bioscience (NAGE) price target decreased by 13.92% to 13.87
The article reports that the price target for Niagen Bioscience (NAGE) has been decreased by 13.92%, bringing it down to $13.87. This change indicates a significant revision in the expected valuation for the company's stock.
Niagen Bioscience (NAGE) price target decreased by 13.92% to 13.87
This article reports a significant decrease in the price target for Niagen Bioscience (NAGE), which has been lowered by 13.92% to 13.87. Further details regarding the reasons for this adjustment or the analysis behind it are not provided within the snippet.
Niagen Bioscience (NAGE) boosts share repurchase authorization to $20 million
Niagen Bioscience (NAGE) announced an increase in its share repurchase authorization from $10 million to $20 million, signaling confidence in its strategy and long-term value. As of March 17, 2026, the company had repurchased approximately $2.6 million under the program, which is authorized through October 31, 2027. The move provides flexibility for returning capital to shareholders and repurchasing shares at attractive prices, although the company is not obligated to repurchase the full amount.
Niagen Bioscience Increases Share Repurchase Program to $20 Million
Niagen Bioscience (NASDAQ: NAGE) has announced an increase in its share repurchase program from $10 million to $20 million, reflecting the company's confidence in its strategy and long-term value. As of March 17, 2026, the company has already repurchased approximately $2.6 million of its common stock. The program is authorized through October 31, 2027, and allows for repurchases through various methods as determined by management.
Niagen Bioscience doubles share buyback program to $20 million By Investing.com
Niagen Bioscience has increased its share repurchase program from $10 million to $20 million, reflecting confidence in its strategy and value, especially as its stock trades near its 52-week low. The company, which has already repurchased $2.6 million, shows a strong financial position with more cash than debt and a high current ratio. This move follows a strong financial quarter where earnings and revenue surpassed analyst expectations, driven by increased Tru Niagen sales and expanding research initiatives.
Niagen Bioscience Increases Share Repurchase Program to $20 Million
Niagen Bioscience, Inc. has announced an increase in its share repurchase program from $10 million to $20 million, signaling the company's confidence in its strategy and long-term value. As of March 17, 2026, the company had already repurchased approximately $2.6 million of its common stock. CEO Rob Fried stated that the company will continue to opportunistically leverage the perceived disconnect between NASDAQ: NAGE's market valuation and its underlying business strength.
Niagen Bioscience Increases Share Repurchase Program to $20 Million
Niagen Bioscience, Inc. (NASDAQ: NAGE) has announced an increase in its share repurchase program from $10 million to $20 million, reflecting the company's confidence in its strategy and long-term value. As of March 17, 2026, the company has already repurchased approximately $2.6 million of its common stock under the program. The CEO, Rob Fried, stated that the company will continue to opportunistically capitalize on the perceived undervaluation of its market position.
Niagen Bioscience raises share buyback authorization to $20M, $2.6M repurchased to date
Niagen Bioscience has increased its share repurchase program authorization from $10.0 million to $20.0 million. To date, the company has repurchased approximately $2.6 million of common stock under this program. The program is now authorized through October 31, 2027, allowing flexibility to return capital to shareholders.
Niagen Bioscience Increases Share Repurchase Program to $20 Million
Niagen Bioscience, Inc. announced an increase to its share repurchase program, raising the total authorization from $10 million to $20 million. CEO Rob Fried stated that this increase reflects the company's confidence in its strategy and long-term value. The company, a global leader in NAD+ science, aims to capitalize on the disconnect between its market valuation and business strength.
Latest NAGE News - Niagen Bioscience Announces Pharmaceutical-...
Niagen Bioscience, formerly ChromaDex Corp., has rebranded and is focusing on NAD+ science and healthy aging with its Niagen® ingredient. The company recently announced the expansion of its pharmaceutical-grade Niagen® IV therapy to nearly 600 clinics nationwide, the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board, and secured a U.S. Patent for nicotinamide riboside salt forms. These developments highlight the company's commitment to scientific advancement, product expansion, and intellectual property protection in the NAD+ market.
Niagen Bioscience Increases Share Repurchase Program to $20 Million
Niagen Bioscience, Inc. announced that its Board of Directors has increased the company's share repurchase program authorization from $10 million to $20 million. CEO Rob Fried stated that this reflects the company's confidence in its strategy and long-term value, and they plan to advantageously repurchase shares given the perceived disconnect between market valuation and business strength. The program is authorized through October 31, 2027.
Niagen Bioscience to Present at the 38th Annual ROTH Conference
Niagen Bioscience, a global authority on NAD+, announced its participation in the 38th Annual ROTH Conference. CEO Rob Fried will speak on the "Technologies Advancing Healthy Aging Panel" and engage in one-on-one meetings with institutional investors, alongside CFO Ozan Pamir. The conference focuses on growth sectors and provides networking opportunities for public and private companies.
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
Niagen Bioscience announced it has surpassed 300 material transfer agreements (MTAs) with global research institutions for its patented nicotinamide riboside (NR) ingredient, Niagen®. This extensive external research program has contributed to 45 published clinical studies, establishing Niagen as the most researched NAD-boosting ingredient worldwide and advancing the understanding of NAD+ biology in healthy aging. The program has generated over $200 million in third-party research value and resulted in a patent portfolio of over 50 granted patents.
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
Niagen Bioscience announced that its external research program for Niagen®, a patented nicotinamide riboside (NR) ingredient, has exceeded 300 material transfer agreements with global research institutions. These agreements have led to 45 published clinical studies on Niagen, making it the most extensively researched NAD-boosting ingredient worldwide. The program highlights growing scientific interest in NAD+ biology and Niagen's role in cellular health, supporting research at institutions like NIH, Mayo Clinic, Harvard, and Cambridge.
National Advertising Division Recommends Niagen Update Tru Niagen NAD+ Claims
The National Advertising Division (NAD) has recommended that Niagen Bioscience, Inc. modify or discontinue certain claims for its Tru Niagen dietary supplement, following a challenge from Reus Research LLC. These claims include explicit assertions of significant NAD+ level increases and health-related benefits. Niagen Bioscience plans to appeal the NAD's decision, which also addressed issues related to organ-specific health claims, consumer testimonials, and influencer marketing practices.
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
Niagen Bioscience announced it has surpassed 300 material transfer agreements with global research institutions for its Niagen® ingredient, establishing it as a leading NAD+ research support program. This extensive research network has contributed to 45 published clinical studies on Niagen, making it the most researched patented NAD-boosting ingredient worldwide. The program highlights Niagen's efficacy in safely elevating NAD+ and its growing recognition in healthy aging research across various health areas.
National Advertising Division Recommends Niagen Modify or Discontinue Certain Tru Niagen NAD+ Claims; Niagen to Appeal
The National Advertising Division (NAD) has recommended that Niagen Bioscience, Inc. modify or discontinue certain claims for its Tru Niagen dietary supplement, following a challenge from Reus Research LLC. These claims include assertions of significant NAD+ level increases and associated health benefits. Niagen Bioscience plans to appeal the NAD's decision, disputing the findings regarding the substantiation of their advertising claims and the interpretation of clinical evidence.
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®
Niagen Bioscience has launched its Niagen® Skincare Innovation Lab and introduced Niagen NanoCloud™, a dermatologist-tested topical skincare product. This marks the company's entry into the growing skincare market, utilizing its patented Niagen® (nicotinamide riboside, or NR) to address NAD+ degradation in water-based skincare. Niagen NanoCloud aims to provide a stable, effective solution for improving skin texture, hydration, and radiance, with insights from its limited release guiding future product development.
Niagen Bioscience Launches Niagen Skincare Innovation Lab
Niagen Bioscience has launched its Skincare Innovation Lab, unveiling Niagen NanoCloud as its first product. This move signals the company's entry into the skincare market, leveraging its NAD+ science expertise. Niagen NanoCloud is designed to overcome the instability of NAD+ in water-based products by using a waterless sachet format, aiming to deliver optimal efficacy for improved skin texture, hydration, and radiance.
New $59 Niagen NanoCloud sachets show smoother, more hydrated skin in 2 weeks
Niagen Bioscience (NASDAQ: NAGE) has launched its Niagen Skincare Innovation Lab and debuted Niagen NanoCloud, a dermatologist-tested topical skincare product powered by patented Niagen (nicotinamide riboside). These $59 sachets are designed to protect potency and deliver a precision-dosed treatment that, according to a consumer study, leads to smoother, more hydrated, and youthful-looking skin within two weeks. The launch marks Niagen Bioscience's entry into the rapidly growing global skincare and anti-aging cosmetics markets.
Niagen Bioscience (NASDAQ:NAGE) Lowered to "Hold" Rating by Wall Street Zen
Wall Street Zen downgraded Niagen Bioscience (NASDAQ:NAGE) from "buy" to "hold," despite the broader consensus remaining a "Moderate Buy" with an average target price of $16. This downgrade followed Niagen's Q4 results beating expectations and annual profit doubling, alongside management's expressed interest in acquisitions and GLP-1-style expansion. However, the company's FY2026 revenue guidance fell below street estimates, leading to analyst cuts in near-term EPS forecasts.
Niagen Bioscience (NAGE) Margin Rise To 13.4% Tests Bullish Narrative Targets
Niagen Bioscience (NAGE) reported Q4 FY 2025 revenue of US$33.8 million and EPS of US$0.05, with full-year revenue at US$129.4 million and EPS at US$0.22, marking a 103.3% jump in earnings and 15.9% revenue growth. The company's net profit margin has improved to 13.4%, prompting investors to scrutinize earnings quality and future growth prospects. Despite positive margin trends and strong earnings growth, the stock trades at a P/E of 23.5x, higher than peers, raising questions about valuation against a DCF fair value of US$23.38 and concerns regarding a high proportion of non-cash earnings.
Niagen Bioscience FY25 Net Sales Jump 30%; Sees 10-15% Growth In FY26
Niagen Bioscience Inc. (NAGE) reported a significant 30% jump in total net sales for full-year 2025, reaching $129.4 million, with net income more than doubling. For FY26, the company projects a 10-15% net sales growth, driven primarily by its e-commerce business and new strategic partnerships, excluding revenue from its Analytical Reference Standards and Services segment. Niagen, a patent-protected form of nicotinamide riboside (NR), is central to the company's products for healthy aging, including the TRU NIAGEN brand.
Niagen Bioscience 2025 Financials: $129.4M Revenue, $17.4M Profit - News and Statistics
Niagen Bioscience Inc. has released its financial results for both the fourth quarter and the full year of 2025. The company reported a quarterly profit of $4.1 million and annual revenue of $129.4 million. For the full fiscal year, Niagen Bioscience achieved a total profit of $17.4 million, translating to 20 cents per share.
Niagen Bioscience Rallies 18% After Hours: Here's Why
Niagen Bioscience Inc. (NASDAQ: NAGE) saw an 18.41% rally in after-hours trading following the announcement of its strongest annual financial performance to date. The company reported a 30% year-over-year increase in net sales for 2025, reaching $129.4 million, and net income doubled to $17.7 million. CEO Rob Fried also indicated the company is actively evaluating acquisition targets, alongside a conservative revenue projection of $145 million for 2026.
Niagen Bioscience (NAGE) Earnings Transcript
Niagen Bioscience (NAGE) reported strong Q4 and full-year 2025 financial results, with significant revenue and net income growth driven by increased e-commerce and Tru Niagen sales. The company is strategically focused on expanding its intellectual property, launching NIAGEN Plus home injection kits, and exploring new markets, while actively defending its market position against NMN competitors through litigation. Scientific research supporting NR's benefits and operational streamlining following the divestiture of non-core assets underpin their optimistic, yet conservative, 2026 outlook with expected backloaded sales growth.
Niagen Bioscience: Fourth Quarter Financial Overview
Niagen Bioscience, Inc. (NAGE) announced its fourth-quarter financial results, reporting a net income of $4.1 million. The company achieved earnings of 5 cents per share, with adjusted earnings at 3 cents per share, and generated $33.8 million in revenue during the quarter. This financial data was provided by Automated Insights, utilizing information from Zacks Investment Research.
Earnings call transcript: Niagen Bioscience’s Q4 2025 revenue grows 16%
Niagen Bioscience reported strong financial results for Q4 2025 and the full year 2025, with Q4 revenue growing 16% year-over-year to $33.8 million and full-year revenue increasing 30% to $129.4 million. The company announced plans to expand its Niagen Plus injectable formulations and Tru Niagen Beauty line, while also addressing litigation against the FDA regarding NMN product status and patent infringements. Scientific research continues to show Niagen's superiority in boosting NAD levels compared to NMN.
Niagen Bioscience: Q4 Earnings Snapshot
Niagen Bioscience, Inc. (NAGE) reported fourth-quarter earnings of $4.1 million, or 5 cents per share, with adjusted earnings of 3 cents per share. The company posted revenue of $33.8 million for the quarter. For the full year, Niagen Bioscience reported a profit of $17.4 million, or 20 cents per share, on revenue of $129.4 million.
Niagen Bioscience more than doubles 2025 profit as Tru Niagen sales jump
Niagen Bioscience reported a 30% year-over-year net sales increase to $129.4 million and a 103% net income increase to $17.4 million for fiscal year 2025, significantly boosted by Tru Niagen sales. The company also announced a positive outlook for 2026, projecting 10-15% net sales growth, excluding its recently sold reference standards segment. Key operational highlights included the sale of its analytical reference standards business, a partnership allowing HSA/FSA payments for Tru Niagen, and the acquisition of core nicotinamide riboside patent portfolio.
Niagen Bioscience (NAGE) doubles 2025 profit and guides 10–15% growth
Niagen Bioscience (NAGE) reported a significant financial performance for 2025, with net sales increasing by 30% to $129.4 million and net income more than doubling to $17.4 million, achieving $0.22 basic EPS. The company also saw its gross margin improve to 64.3% and Adjusted EBITDA rise to $20.4 million. Looking ahead to 2026, Niagen Bioscience forecasts 10-15% net sales growth and slightly higher margins, driven by strategic investments in marketing, R&D, and infrastructure.
Niagen Bioscience To Streamline Operations With The Sale Of Chromadex Reference Standards Business To LGC
Niagen Bioscience is set to streamline its operations by selling its Chromadex Reference Standards Business to LGC. This strategic move is part of the company's efforts to enhance efficiency. The transaction involves mergers and acquisitions within the US stocks market.
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen
Niagen Bioscience has secured a new U.S. Patent (No. 12,558,367) that covers intravenous and injectable formulations and methods of use for Nicotinamide Riboside (NR), specifically its Niagen® ingredient. This patent expands the company's intellectual property portfolio into IV and injectable delivery formats, protecting its exclusivity in this growing market segment through 2044. The company's Niagen Plus product offers a next-generation IV formulation that supports faster infusions and improved NAD+ levels with fewer side effects compared to traditional NAD+ IVs.
Niagen Flat on Patent News
Niagen Bioscience, Inc. (NASDAQ: NAGE) announced the granting of U.S. Patent No. 12,558,367, which expands its intellectual property for nicotinamide riboside (NR) into intravenous and injectable formulations, with protection expected through 2044. This patent supports Niagen's exclusivity for its Niagen Plus product, an IV formulation designed for faster infusions and better NAD+ level elevation without severe side effects compared to traditional NAD+ IV. Despite this news, NAGE shares saw a slight dip, closing down a penny at $5.10.
Niagen Bioscience (NAGE) CFO receives grant of 62,131 employee stock options
Niagen Bioscience (NAGE) CFO Pamir Ozan was granted 62,131 employee stock options as part of his compensation, as reported in a Form 4 SEC filing. These options, awarded at no cost, will vest over four years, with one-fourth vesting annually from the grant date of February 19, 2026. This grant ties his potential ownership benefits to his continued service and aligns his incentives with the company's long-term performance.
Niagen Bioscience (NAGE) SVP and General Counsel receives 41,420 stock options
Niagen Bioscience (NAGE) SVP and General Counsel, Carlos Luis Lopez, was granted 41,420 employee stock options on February 19, 2026. These options were awarded at no purchase price and will vest in four equal annual installments starting one year from the grant date. This transaction was reported in a Form 4 SEC filing, indicating an increase in his potential future equity stake in the company.
Hillsdale Investment Management Inc. Buys Shares of 320,272 Niagen Bioscience, Inc. $NAGE
Hillsdale Investment Management Inc. recently acquired a new stake of 320,272 shares in Niagen Bioscience, valued at approximately $2.99 million, representing about 0.40% ownership. The stock (NASDAQ:NAGE) opened at $4.86, significantly below the average analyst price target of $14.28, despite a "Moderate Buy" consensus rating from analysts. Several other institutional investors also modified their holdings in Niagen Bioscience during the third quarter.
Niagen Bioscience, Inc. (NAGE) Stock Analysis: A 219.84% Potential Upside Awaits Investors
Niagen Bioscience, Inc. (NAGE) is highlighted as a compelling investment opportunity in the healthy aging product sector, with analysts projecting a significant upside potential of 219.84%. The company, known for its nicotinamide riboside ingredient, exhibits strong financial metrics such as a 32.90% revenue growth rate and a 38.90% return on equity. Despite current stock performance below moving averages, strong analyst consensus and a focus on reinvesting earnings for growth suggest long-term success.
Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen
Niagen Bioscience announced its role as the premiere sponsor for the inaugural "NAD for Health: Opportunities & Challenges" conference hosted by the University of Copenhagen, scheduled for March 23-25, 2026. This scientific forum aims to advance NAD+ (nicotinamide adenine dinucleotide) science by fostering dialogue among experts from various disciplines. The conference will address the translation of NAD metabolism research into clinical applications, focusing on trial design, biomarkers, and regulatory considerations, with themes including NAD+ precursor strategies for orphan diseases and neurodegenerative diseases.
Niagen Bioscience is the Premiere Sponsor of the Inaugural "NAD for Health: Opportunities & Challenges" Conference Hosted by the University of Copenhagen
Niagen Bioscience, Inc. (NASDAQ: NAGE) announced its premiere sponsorship of the inaugural "NAD for Health: Opportunities & Challenges" scientific meeting, hosted by the University of Copenhagen. This three-day conference, scheduled for March 23-25, 2026, will gather leading NAD experts to foster evidence-based dialogue and accelerate clinical translation in NAD metabolism and its implications for human health. The event aims to address barriers to translation in NAD science, including trial design, biomarkers, and regulatory considerations.
Niagen Bioscience Sponsors Inaugural NAD for Health Conference
Niagen Bioscience is the primary sponsor of the first "NAD for Health: Opportunities & Challenges" scientific meeting in Copenhagen from March 23-25, 2026. This conference aims to advance NAD+ science and healthy aging research by bringing together experts to discuss NAD metabolism, rare diseases, healthspan extension, and neurodegenerative diseases. The event will include thematic sessions, a panel discussion, and a dedicated poster session, with a global livestream to ensure broad access to the latest research.
